
November 6, 2017 - By Clifton Ray
Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It fall, as 78 investors sold Bristol-Myers Squibb Co shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Oppenheimer Asset Mgmt holds 232,376 shares. Osterweis Mngmt Incorporated invested 0.07% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). 600 are owned by Orrstown Fincl Ser. Finemark Bankshares owns 122,423 shares. California State Teachers Retirement Sys has invested 0.37% in Bristol-Myers Squibb Co (NYSE:BMY). Mcgowan Grp Asset Mgmt Incorporated reported 3,622 shares or 0.04% of all its holdings. Baldwin Brothers Ma owns 0.02% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 2,329 shares. Compton Cap Management Ri owns 0.93% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 36,712 shares. Winch Advisory Service Limited Liability holds 0% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 36 shares. First Advsrs Ltd Partnership reported 433,050 shares. Community Bancorporation Na accumulated 35,873 shares. Dumont And Blake Invest Ltd Company owns 23,250 shares. Dodge And Cox has invested 1.39% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Monroe National Bank Tru Mi owns 0.03% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 1,893 shares. Teacher Retirement System Of Texas reported 0.29% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY).They currently have a $61 price target on Bristol-Myers Squibb (NYSE:BMY). The target price by Credit Suisse would suggest a potential downside of -1.10 % from the company’s previous stock close. This has been released in analysts report on 27 October.Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It fall, as 78 investors sold Bristol-Myers Squibb Co shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Oppenheimer Asset Mgmt holds 232,376 shares. Osterweis Mngmt Incorporated invested 0.07% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). 600 are owned by Orrstown Fincl Ser. Finemark Bankshares owns 122,423 shares. California State Teachers Retirement Sys has invested 0.37% in Bristol-Myers Squibb Co (NYSE:BMY). Mcgowan Grp Asset Mgmt Incorporated reported 3,622 shares or 0.04% of all its holdings. Baldwin Brothers Ma owns 0.02% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 2,329 shares. Compton Cap Management Ri owns 0.93% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 36,712 shares. Winch Advisory Service Limited Liability holds 0% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 36 shares. First Advsrs Ltd Partnership reported 433,050 shares. Community Bancorporation Na accumulated 35,873 shares. Dumont And Blake Invest Ltd Company owns 23,250 shares. Dodge And Cox has invested 1.39% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Monroe National Bank Tru Mi owns 0.03% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 1,893 shares. Teacher Retirement System Of Texas reported 0.29% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY).Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.80’s average target is 1.82% above currents $61.68 stock price. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Citigroup with “Buy” on Wednesday, October 25. The firm earned “Buy” rating on Monday, July 17 by Jefferies. Jefferies maintained it with “Hold” rating and $65 target in Tuesday, March 15 report. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 23. The rating was maintained by Cowen & Co with “Hold” on Monday, September 18. The rating was initiated by Hilliard Lyons on Monday, May 23 with “Neutral”. The firm earned “Equal-Weight” rating on Friday, October 13 by Barclays Capital. The rating was upgraded by Piper Jaffray to “Underweight” on Monday, August 24. The rating was downgraded by Berenberg on Thursday, August 11 to “Hold”. BMO Capital Markets downgraded the shares of BMY in report on Monday, January 25 to “Market Perform” rating.The stock decreased 0.87% or $0.54 during the last trading session, reaching $61.68. About 3.58 million shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 6, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has market cap of $100.95 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 24.26 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Gurufocus.com which released: “Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company …” on October 17, 2017, also Gurufocus.com with their article: “First Quadrant LP Buys Boeing Co, Vanguard REIT, Bristol-Myers Squibb Company …” published on October 25, 2017, Investorplace.com published: “Bristol-Myers Squibb Co (BMY) Sees Downgradeâ€¦.. Poor Earnings Momentum” on November 03, 2017. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Nasdaq.com and their article: “Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line” published on October 26, 2017 as well as Streetinsider.com‘s news article titled: “Jefferies Downgrades Bristol-Myers Squibb Co. (BMY) to Hold” with publication date: October 16, 2017.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
